Trexquant Investment LP Has $18.55 Million Stock Holdings in Incyte Co. (NASDAQ:INCY)

Trexquant Investment LP raised its holdings in Incyte Co. (NASDAQ:INCY - Free Report) by 82.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 295,414 shares of the biopharmaceutical company's stock after purchasing an additional 133,769 shares during the period. Incyte comprises 0.4% of Trexquant Investment LP's holdings, making the stock its 29th largest position. Trexquant Investment LP owned about 0.13% of Incyte worth $18,549,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Commonwealth Equity Services LLC lifted its position in shares of Incyte by 12.3% in the third quarter. Commonwealth Equity Services LLC now owns 20,009 shares of the biopharmaceutical company's stock valued at $1,156,000 after acquiring an additional 2,197 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in Incyte by 100.4% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 25,097 shares of the biopharmaceutical company's stock worth $1,450,000 after buying an additional 12,576 shares in the last quarter. Fifth Third Bancorp lifted its position in Incyte by 39.2% during the third quarter. Fifth Third Bancorp now owns 5,828 shares of the biopharmaceutical company's stock worth $337,000 after buying an additional 1,642 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Incyte by 1.7% during the third quarter. Teacher Retirement System of Texas now owns 50,190 shares of the biopharmaceutical company's stock worth $2,899,000 after buying an additional 847 shares in the last quarter. Finally, New Mexico Educational Retirement Board lifted its position in Incyte by 7.8% during the third quarter. New Mexico Educational Retirement Board now owns 9,650 shares of the biopharmaceutical company's stock worth $557,000 after buying an additional 700 shares in the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on INCY shares. Jefferies Financial Group started coverage on Incyte in a research report on Friday, February 23rd. They issued a "buy" rating and a $81.00 target price on the stock. Citigroup reduced their target price on Incyte from $82.00 to $81.00 and set a "buy" rating on the stock in a research report on Wednesday, February 14th. StockNews.com cut Incyte from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 2nd. Stifel Nicolaus lifted their price objective on Incyte from $67.00 to $68.00 and gave the company a "hold" rating in a research note on Wednesday, February 14th. Finally, Truist Financial reaffirmed a "buy" rating and issued a $83.00 price objective (down from $84.00) on shares of Incyte in a research note on Wednesday, May 1st. Nine equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, Incyte presently has an average rating of "Moderate Buy" and a consensus price target of $74.93.

Incyte Stock Up 0.2 %

INCY traded up $0.09 on Monday, hitting $57.19. 1,977,879 shares of the company were exchanged, compared to its average volume of 1,892,073. The company has a market cap of $12.84 billion, a price-to-earnings ratio of 17.29, a price-to-earnings-growth ratio of 1.75 and a beta of 0.69. The company has a current ratio of 3.47, a quick ratio of 3.43 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $55.26 and a two-hundred day moving average price of $57.64. Incyte Co. has a twelve month low of $50.27 and a twelve month high of $67.36.

Incyte Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.